RPRX - Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
As of Jun 30, 2026: spot at $56.39, ATM IV 22.3%, max pain $40.00, net GEX $1.2M.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Market Cap
- $24.19B
- P/E Ratio
- 29.34
- Beta
- 0.42
- 52-Week Range
- 34.081-56.5
- Dividend Yield
- $0.91
- CEO
- Pablo Legorreta
- Employees
- 100
- IPO Date
- Jun 16, 2020
- Exchange
- NASDAQ
What RPRX Looks Like to Options Traders Today
IV rank of 9.8% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($1.2M) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.388) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The RPRX overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked RPRX overview questions
- What is RPRX?
- RPRX is the ticker symbol for Royalty Pharma plc, a listed security. Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. Listed on NASDAQ. RPRX is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the RPRX options snapshot look like today?
- As of Jun 30, 2026, the RPRX options snapshot shows spot at $56.39, ATM IV 22.3%, IV rank 9.8%, max pain $40.00, net GEX $1.2M, expected move 6.39%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are RPRX's key statistics?
- Royalty Pharma plc (RPRX) carries a market capitalization of $24.19B, trailing P/E ratio of 29.34, beta of 0.42 relative to the broader market, 52-week range of 34.081-56.5. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does RPRX belong to?
- Royalty Pharma plc operates in the Healthcare sector, in the Medical - Pharmaceuticals industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare RPRX's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the RPRX data on this page?
- The options snapshot above is dated Jun 30, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).